Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025

バイオシミラーの世界市場予測:製品別(インスリン、インターフェロン、エタネルセプト、インフリキシマブ、リツキシマブ、グルカゴン、カルシトニン)、製造別(社内、契約)、疾患別(腫瘍、慢性疾患、血液疾患、自己免疫疾患)、地域別

◆タイトル:Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025
◆商品コード:BT 2160
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年3月30日
◆ページ数:187
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥593,250見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥698,250見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥855,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社はバイオシミラーの世界市場が、2020年118憶ドルから2025年357憶ドルまで、年平均24.7%成長すると予測しています。本調査レポートでは、バイオシミラーの世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、規制動向、市場動向、製品別(インスリン、インターフェロン、エタネルセプト、インフリキシマブ、リツキシマブ、グルカゴン、カルシトニン)分析、製造別(社内、契約)分析、疾患別(腫瘍、慢性疾患、血液疾患、自己免疫疾患)分析、地域別分析、競争状況、企業概要などを含め、次の構成でお届け致します。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・規制動向
・市場動向
・バイオシミラーの世界市場:製品別(インスリン、インターフェロン、エタネルセプト、インフリキシマブ、リツキシマブ、グルカゴン、カルシトニン)
・バイオシミラーの世界市場:製造別(社内、契約)
・バイオシミラーの世界市場:疾患別(腫瘍、慢性疾患、血液疾患、自己免疫疾患)
・バイオシミラーの世界市場:地域別
・競争状況
・企業概要

“The global biosimilars market size is projected to register a CAGR of 24.7% during the forecast period.”
The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. Growth in this industry is driven by the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. On the other hand, complexities in manufacturing restraining the market.

“The monoclonal antibody segment is anticipated to grow at the fastest growth rate during the forecast period.”
The biosimilars market by service is categorized into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, and teriparatide and enoxaparin sodium. The monoclonal antibodies segment is expected to register the highest CAGR during the forecast period. The growth of this segment is driven mainly by the increasing number of product launches/approvals, rising incidences of cancer diseases.

“The contract manufacturing segment is estimated to grow at a rapid rate during the analysis period.”
Based on the treatment site, the biosimilars market is segmented into in-house manufacturing and contract manufacturing. The contract manufacturing segment is expected to remain the fastest-growing segment of the global market during the biosimilars period. Its benefits, particularly for small players in the market or those that do not have sufficient infrastructure and resources for efficient manufacturing, are driving growth.

“Asia Pacific is estimated to register the highest CAGR during the study period.”
Geographically, the biosimilars market is dominated by Europe and followed by Asia Pacific in 2019. However, the Asia Pacific region is estimated to grow at the fastest rate during forecast to period. The rising aging population, coupled with the massive demand for cost-effective alternative pharmaceuticals, will drive the market in the region over the forecast period.

Breakdown of Profiles of Primary Participants:
• By Company Type: Tier 1: 32%, Tier 2: 44%, and Tier 3: 24%
• By Designation: C-level: 30%, Director-level: 34%, and Others: 36%
• By Region: North America: 40%, Europe: 28%, Asia Pacific: 20%, and the Rest of the World: 12%

The key players in the biosimilars market include Pfizer (US), Sandoz (Germany), Biocon (India), Biogen (US), Fresenius Kabi AG (Germany), Boehringer Ingelheim (Germany), Merck KgaA, Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy’s Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany).

Research Coverage:
The report analyzes the biosimilars market by product, type of manufacturing, indication, and region. Apart from comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by market players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.

Key Benefits of Buying the Report:
This report will enable both established firms and new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help these firms garner greater market shares. Firms purchasing the report can use any one, or a combination of the below mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the services of the top players in the biosimilars market
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market
• Market Development: Detailed information about emerging markets.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market

【レポートの目次】

1 INTRODUCTION (Page No. – 20)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.4 YEARS CONSIDERED FOR THE STUDY
1.5 CURRENCY
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 23)
2.1 RESEARCH DATA
2.2 SECONDARY DATA
2.2.1 SECONDARY SOURCES
2.3 PRIMARY DATA
2.3.1 KEY DATA FROM PRIMARY SOURCES
2.4 MARKET SIZE ESTIMATION
2.4.1 BOTTOM-UP APPROACH
2.4.2 GROWTH FORECAST
2.4.3 TOP-DOWN APPROACH
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 ASSUMPTIONS FOR THE STUDY
2.7 LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. – 30)

4 PREMIUM INSIGHTS (Page No. – 33)
4.1 BIOSIMILARS MARKET OVERVIEW
4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2019
4.3 GEOGRAPHICAL SNAPSHOT OF THE BIOSIMILARS MARKET

5 REGULATORY OUTLOOK (Page No. – 36)
5.1 NORTH AMERICA
5.1.1 US
5.1.2 CANADA
5.2 EUROPE
5.3 ASIA PACIFIC
5.3.1 CHINA
5.3.2 INDIA
5.3.3 JAPAN
5.3.4 SOUTH KOREA
5.3.5 AUSTRALIA
5.4 REST OF THE WORLD
5.4.1 BRAZIL
5.4.2 MEXICO
5.4.3 ARGENTINA
5.4.4 SAUDI ARABIA

6 MARKET OVERVIEW (Page No. – 40)
6.1 INTRODUCTION
6.2 MARKET DYNAMICS
6.2.1 DRIVERS
6.2.1.1 Increasing demand for biosimilar drugs
6.2.1.2 Rising incidence of chronic diseases
6.2.2 RESTRAINTS
6.2.2.1 Complexities in manufacturing
6.2.2.2 Resistance from biologic manufacturers
6.2.3 OPPORTUNITIES
6.2.3.1 Emerging markets
6.2.3.2 New indications and the patent expiry of biologic products
6.2.4 CHALLENGES
6.2.4.1 Stringent regulatory requirements
6.2.5 TRENDS
6.2.5.1 Collaborations for biosimilar research and clinical trials

7 BIOSIMILARS MARKET, BY PRODUCT (Page No. – 46)
7.1 INTRODUCTION
7.2 MONOCLONAL ANTIBODIES
7.2.1 INFLIXIMAB
7.2.1.1 Infliximab accounted for the largest share of the monoclonal antibodies market
7.2.2 RITUXIMAB
7.2.2.1 Rising incidence of autoimmune diseases and cancer are key drivers for the market growth
7.2.3 TRASTUZUMAB
7.2.3.1 Rising incidences of cancer will drive market growth
7.2.4 ADALIMUMAB
7.2.4.1 Adalimumab will register the highest CAGR in the monoclonal antibodies market
7.2.5 OTHER MONOCLONAL ANTIBODIES
7.3 INSULIN
7.3.1 INCREASING INCIDENCE OF DIABETES WILL SUPPORT MARKET GROWTH
7.4 GRANULOCYTE COLONY-STIMULATING FACTOR
7.5 ERYTHROPOIETIN
7.5.1 RISING INCIDENCE OF BLOOD DISORDERS WILL DRIVE MARKET GROWTH
7.6 RECOMBINANT HUMAN GROWTH HORMONE
7.6.1 MARKET GROWTH IS DRIVEN PRIMARILY BY THE INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS
7.7 ETANERCEPT
7.7.1 APAC MARKET FOR ETANERCEPT WILL SHOW THE HIGHEST GROWTH IN THE FORECAST PERIOD
7.8 FOLLITROPIN
7.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT WILL DRIVE MARKET GROWTH
7.9 TERIPARATIDE
7.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS IS THE MAIN GROWTH DRIVER FOR THIS MARKET
7.10 INTERFERONS
7.10.1 MARKET GROWTH IS SUPPORTED BY THE RISING INCIDENCE OF INFECTIOUS DISEASES
7.11 ENOXAPARIN SODIUM
7.11.1 WIDE RANGE OF APPLICATIONS HAVE SUPPORTED THE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS
7.12 GLUCAGON
7.12.1 SANDOZ IS A MAJOR PLAYER IN THE GLUCAGON BIOSIMILARS MARKET
7.13 CALCITONIN
7.13.1 INCREASING INCIDENCE OF OSTEOPOROSIS WILL DRIVE THE MARKET

8 BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING (Page No. – 61)
8.1 INTRODUCTION
8.2 IN-HOUSE MANUFACTURING
8.2.1 COST-EFFECTIVENESS MAKES IN-HOUSE MANUFACTURING HIGHLY PREFERABLE FOR MOST MARKET PLAYERS
8.3 CONTRACT MANUFACTURING
8.3.1 OUTSOURCING PRODUCTION ENABLES COMPANIES TO FOCUS ON CORE COMPETENCY AND PROVIDES COST-BENEFITS

9 BIOSIMILARS MARKET, BY INDICATION (Page No. – 65)
9.1 INTRODUCTION
9.2 ONCOLOGY
9.2.1 RISING BURDEN OF CANCER AND GROWING INCIDENCE HAVE DRIVEN DEMAND FOR BIOSIMILARS
9.3 CHRONIC DISEASES
9.3.1 HIGH EFFICACY OF BIOSIMILARS HAS DRIVEN RESEARCH INTO APPLICATIONS IN CHRONIC DISEASE TREATMENT
9.4 AUTOIMMUNE DISEASES
9.4.1 GROWING RESEARCH ACTIVITY FOR AUTOIMMUNE DISEASE INDICATIONS WILL FAVOR MARKET GROWTH
9.5 BLOOD DISORDERS
9.5.1 POSSIBILITY OF COST-REDUCTIONS IN BLOOD DISORDER TREATMENT WILL SUPPORT MARKET DEMAND FOR BIOSIMILARS
9.6 GROWTH HORMONE DEFICIENCY
9.6.1 GROWING CASES OF GH DEFICIENCY DRIVES DEMAND FOR BIOSIMILARS
9.7 INFECTIOUS DISEASES
9.7.1 ASIA PACIFIC SHOWS HIGHEST DEMAND FOR BIOSIMILARS IN THIS SEGMENT
9.8 OTHER INDICATIONS

10 BIOSIMILARS MARKET, BY REGION (Page No. – 76)
10.1 INTRODUCTION
10.2 EUROPE
10.2.1 UK
10.2.1.1 The UK holds the largest share of the biosimilars market in Europe
10.2.2 FRANCE
10.2.2.1 Rising geriatric population will drive market growth
10.2.3 GERMANY
10.2.3.1 The presence of a favorable pricing system has supported biosimilar adoption in Germany
10.2.4 ITALY
10.2.4.1 Rising geriatric population in Italy will support market growth
10.2.5 SPAIN
10.2.5.1 R&D investments for the development of innovative drugs is a key growth driver in the Spanish market
10.2.6 REST OF EUROPE
10.3 ASIA PACIFIC
10.3.1 INDIA
10.3.1.1 India holds the largest share of the APAC market
10.3.2 CHINA
10.3.2.1 China accounts for the second-largest share of the APAC market
10.3.3 SOUTH KOREA
10.3.3.1 Rising incidences of chronic diseases are expected to drive the market in South Korea
10.3.4 JAPAN
10.3.4.1 Growing geriatric population is expected to drive the market in Japan
10.3.5 AUSTRALIA
10.3.5.1 Increasing number of product launches by companies will drive market growth
10.3.6 REST OF ASIA PACIFIC
10.4 NORTH AMERICA
10.4.1 US
10.4.1.1 US will dominate the North American biosimilars market
10.4.2 CANADA
10.4.2.1 Increasing incidences of chronic diseases will drive market growth in Canada
10.5 LATIN AMERICA
10.5.1 RISING INCIDENCES OF CANCER WILL DRIVE MARKET GROWTH
10.6 MIDDLE EAST AND AFRICA
10.6.1 FAVORABLE HEALTHCARE REFORMS AND INFRASTRUCTURAL DEVELOPMENT WILL FAVOR MARKET GROWTH

11 COMPETITIVE LANDSCAPE (Page No. – 135)
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS, 2018
11.3 COMPETITIVE SCENARIO
11.3.1 PRODUCT LAUNCHES/PRODUCT APPROVALS
11.3.2 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
11.3.3 ACQUISITIONS
11.3.4 EXPANSIONS
11.4 COMPETITIVE LEADERSHIP MAPPING (2018)
11.4.1 VENDOR INCLUSION CRITERIA
11.4.2 VISIONARY LEADERS
11.4.3 INNOVATORS
11.4.4 DYNAMIC DIFFERENTIATORS
11.4.5 EMERGING COMPANIES

12 COMPANY PROFILES (Page No. – 141)
12.1 SANDOZ
12.1.1 BUSINESS OVERVIEW
12.1.2 PRODUCTS OFFERED
12.1.3 PRODUCT PIPELINE
12.1.4 RECENT DEVELOPMENTS
12.1.5 MNM VIEW
12.2 PFIZER
12.2.1 BUSINESS OVERVIEW
12.2.2 PRODUCTS OFFERED
12.2.3 PRODUCT PIPELINE
12.2.4 RECENT DEVELOPMENTS
12.2.5 MNM VIEW
12.3 ELI LILLY
12.3.1 BUSINESS OVERVIEW
12.3.2 PRODUCTS OFFERED
12.3.3 MNM VIEW
12.4 TEVA PHARMACEUTICAL
12.4.1 BUSINESS OVERVIEW
12.4.2 PRODUCTS OFFERED
12.4.3 PRODUCT PIPELINE
12.4.4 RECENT DEVELOPMENTS
12.5 CELLTRION
12.5.1 BUSINESS OVERVIEW
12.5.2 PRODUCTS OFFERED
12.5.3 PRODUCT PIPELINE
12.5.4 RECENT DEVELOPMENTS
12.6 BIOCON
12.6.1 BUSINESS OVERVIEW
12.6.2 PRODUCTS OFFERED
12.6.3 PRODUCT PIPELINE
12.6.4 RECENT DEVELOPMENTS
12.7 AMGEN
12.7.1 BUSINESS OVERVIEW
12.7.2 PRODUCTS OFFERED
12.7.3 PRODUCT PIPELINE
12.7.4 RECENT DEVELOPMENTS
12.8 SAMSUNG BIOLOGICS
12.8.1 BUSINESS OVERVIEW
12.8.2 PRODUCTS OFFERED
12.8.3 PRODUCT PIPELINE
12.8.4 RECENT DEVELOPMENTS
12.9 MYLAN
12.9.1 BUSINESS OVERVIEW
12.9.2 PRODUCTS OFFERED
12.9.3 RECENT DEVELOPMENTS
12.10 DR. REDDY’S LABORATORIES
12.10.1 BUSINESS OVERVIEW
12.10.2 PRODUCTS OFFERED
12.10.3 RECENT DEVELOPMENTS
12.11 STADA ARZNEIMITTEL AG
12.11.1 BUSINESS OVERVIEW
12.11.2 PRODUCTS OFFERED
12.11.3 RECENT DEVELOPMENTS
12.12 COHERUS BIOSCIENCES
12.12.1 BUSINESS OVERVIEW
12.12.2 PRODUCTS OFFERED
12.12.3 PRODUCT PIPELINE
12.12.4 RECENT DEVELOPMENTS
12.13 BIOCAD
12.13.1 BUSINESS OVERVIEW
12.13.2 PRODUCTS OFFERED
12.13.3 PRODUCT PIPELINE
12.13.4 RECENT DEVELOPMENTS
12.14 AMEGA BIOTECH
12.14.1 BUSINESS OVERVIEW
12.14.2 PRODUCTS OFFERED
12.15 PROBIOMED
12.15.1 BUSINESS OVERVIEW
12.15.2 PRODUCTS OFFERED
12.16 BOEHRINGER INGELHEIM
12.16.1 BUSINESS OVERVIEW
12.16.2 PRODUCTS OFFERED
12.17 APOTEX
12.17.1 BUSINESS OVERVIEW
12.17.2 PRODUCTS OFFERED
12.17.3 RECENT DEVELOPMENTS
12.18 FRESENIUS KABI
12.18.1 BUSINESS OVERVIEW
12.18.2 PRODUCTS OFFERED
12.18.3 PRODUCT PIPELINE
12.18.4 RECENT DEVELOPMENTS
12.19 GEDEON RICHTER
12.19.1 BUSINESS OVERVIEW
12.19.2 PRODUCTS OFFERED
12.19.3 PRODUCT PIPELINE
12.19.4 RECENT DEVELOPMENTS
12.20 MABXIENCE
12.20.1 BUSINESS OVERVIEW
12.20.2 PRODUCTS OFFERED
12.20.3 PRODUCT PIPELINE
12.20.4 RECENT DEVELOPMENTS

13 APPENDIX (Page No. – 176)
13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS

LIST OF TABLES (132 Tables)

TABLE 1 STATUS OF REGULATORY PATHWAY IN NORTH AMERICA
TABLE 2 SUBSTITUTION STATUS IN EUROPEAN COUNTRIES
TABLE 3 STATUS OF REGULATORY PATHWAY IN ASIA PACIFIC
TABLE 4 STATUS OF REGULATORY PATHWAY IN ROW COUNTRIES
TABLE 5 LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
TABLE 6 MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2017–2020)
TABLE 7 BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 8 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 9 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 10 BIOSIMILARS MARKET FOR INFLIXIMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 11 BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 12 BIOSIMILARS MARKET FOR TRASTUZUMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 13 BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 14 BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 15 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 16 LIST OF APPROVED BIOSIMILARS FOR G-CSF
TABLE 17 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018–2025 (USD MILLION)
TABLE 18 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
TABLE 19 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 20 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018–2025 (USD MILLION)
TABLE 21 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2018–2025 (USD MILLION)
TABLE 22 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 23 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2018–2025 (USD MILLION)
TABLE 24 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 25 BIOSIMILARS MARKET FOR ENOXAPARIN SODIUM, BY REGION, 2018–2025 (USD MILLION)
TABLE 26 BIOSIMILARS MARKET FOR GLUCAGON, BY REGION, 2018–2025 (USD MILLION)
TABLE 27 BIOSIMILARS MARKET FOR CALCITONIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 28 BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 29 BIOSIMILARS MARKET FOR IN-HOUSE MANUFACTURING, BY REGION, 2016–2023 (USD BILLION)
TABLE 30 BIOSIMILARS MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2018–2025 (USD MILLION)
TABLE 31 BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 32 BIOSIMILARS APPROVED BY THE US FDA FOR ONCOLOGICAL INDICATIONS, 2017–2019
TABLE 33 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2018–2025 (USD MILLION)
TABLE 34 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2018–2025 (USD MILLION)
TABLE 35 BIOSIMILARS APPROVED BY THE US FDA FOR CHRONIC DISEASES, 2017–2019
TABLE 36 BIOSIMILARS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2018–2025 (USD MILLION)
TABLE 37 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 38 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2018–2025 (USD MILLION)
TABLE 39 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018–2025 (USD MILLION)
TABLE 40 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 41 BIOSIMILARS MARKET, BY REGION, 2018–2025 (USD BILLION)
TABLE 42 LIST OF BIOSIMILARS APPROVED IN EUROPE
TABLE 43 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 44 EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 45 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 46 EUROPE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 47 EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 48 LIST OF BIOSIMILARS IN THE UK
TABLE 49 UK: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 50 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 51 UK: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 52 UK: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 53 FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 54 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 55 FRANCE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 56 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 57 LIST OF BIOSIMILARS APPROVED IN GERMANY
TABLE 58 GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 59 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 60 GERMANY: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 61 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 62 ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 63 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 64 ITALY: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 65 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 66 SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 67 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 68 SPAIN: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 69 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 70 ROE: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 71 ROE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 72 ROE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 73 ROE: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 74 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 75 ASIA PACIFIC: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 76 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 77 ASIA PACIFIC: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 78 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 79 BIOSIMILARS APPROVED AND MARKETED IN INDIA
TABLE 80 INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 81 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 82 INDIA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 83 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 84 BIOSIMILARS APPROVED IN CHINA
TABLE 85 CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 86 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 87 CHINA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 88 CHINA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 89 LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA
TABLE 90 SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 91 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 92 SOUTH KOREA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 93 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 94 LIST OF BIOSIMILARS APPROVED IN JAPAN
TABLE 95 JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 96 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 97 JAPAN: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 98 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 99 LIST OF BIOSIMILARS APPROVED IN AUSTRALIA
TABLE 100 AUSTRALIA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 101 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 102 AUSTRALIA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 103 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 104 LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
TABLE 105 LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
TABLE 106 LIST OF BIOSIMILARS APPROVED IN MALAYSIA
TABLE 107 ROAPAC: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 108 ROAPAC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 109 ROAPAC: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 110 ROAPAC: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 111 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 112 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 113 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 114 NORTH AMERICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 115 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 116 LIST OF BIOSIMILARS APPROVED IN THE US
TABLE 117 US: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 118 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 119 US: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 120 US: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 121 LIST OF BIOSIMILARS APPROVED IN CANADA
TABLE 122 CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 123 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 124 CANADA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 125 CANADA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 126 LIST OF BIOSIMILARS APPROVED IN LATIN AMERICA
TABLE 127 LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 128 LATIN AMERICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 129 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 130 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 131 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 132 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)

LIST OF FIGURES (46 Figures)

FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 4 TOP-DOWN APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 BIOSIMILARS MARKET, BY PRODUCT, 2020 VS. 2025 (USD BILLION)
FIGURE 7 BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2020 VS. 2025 (USD BILLION)
FIGURE 8 BIOSIMILARS MARKET, BY INDICATION, 2020 VS. 2025 (USD MILLION)
FIGURE 9 BIOSIMILARS MARKET, BY REGION, 2020 VS. 2025 (USD BILLION)
FIGURE 10 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE MARKET
FIGURE 11 INSULIN HELD LARGEST MARKET SHARE IN 2019
FIGURE 12 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 13 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
FIGURE 14 INCREASING GERIATRIC POPULATION, BY REGION, 2019 VS. 2050
FIGURE 15 GLOBAL INCIDENCE OF DIABETES, BY REGION, 2019, 2030, 2045
FIGURE 16 ONCOLOGY SEGMENT TO DOMINATE THE BIOSIMILARS MARKET
FIGURE 17 ARTICLES PUBLISHED ON BIOSIMILARS FOR ONCOLOGY, 2010–2018
FIGURE 18 ARTICLES PUBLISHED ON BIOSIMILARS FOR CHRONIC DISEASES, 2010–2018
FIGURE 19 ARTICLES PUBLISHED ON BIOSIMILARS FOR AUTOIMMUNE DISEASES, 2010–2018
FIGURE 20 ARTICLES PUBLISHED ON BIOSIMILARS FOR BLOOD DISORDERS, 2010–2018
FIGURE 21 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE BIOSIMILARS MARKET DURING THE FORECAST PERIOD
FIGURE 22 EUROPE: BIOSIMILARS MARKET SNAPSHOT
FIGURE 23 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN THE UK, 2010–2018
FIGURE 24 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN FRANCE, 2010–2018
FIGURE 25 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN GERMANY, 2010–2018
FIGURE 26 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN ITALY, 2011–2019
FIGURE 27 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN SPAIN, 2010–2018
FIGURE 28 ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT
FIGURE 29 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN THE US, 2010–2018
FIGURE 30 PROJECTED INCREASE IN CANCER INCIDENCE IN CANADA
FIGURE 31 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN CANADA, 2010–2018
FIGURE 32 KEY DEVELOPMENTS OF MAJOR PLAYERS FROM 2017 TO 2020
FIGURE 33 GLOBAL BIOSIMILARS MARKET SHARE ANALYSIS, BY KEY PLAYER 2018
FIGURE 34 MNM DIVE-VENDOR COMPARISON MATRIX: BIOSIMILARS MARKET
FIGURE 35 SANDOZ: COMPANY SNAPSHOT
FIGURE 36 PFIZER: COMPANY SNAPSHOT
FIGURE 37 ELI LILLY: COMPANY SNAPSHOT
FIGURE 38 TEVA PHARMACEUTICAL: COMPANY SNAPSHOT
FIGURE 39 CELLTRION: COMPANY SNAPSHOT
FIGURE 40 BIOCON: COMPANY SNAPSHOT
FIGURE 41 AMGEN: COMPANY SNAPSHOT
FIGURE 42 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
FIGURE 43 MYLAN: COMPANY SNAPSHOT
FIGURE 44 DR. REDDY’S LABORATORIES: COMPANY SNAPSHOT
FIGURE 45 STADA ARZNEIMITTEL: COMPANY SNAPSHOT
FIGURE 46 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT



★調査レポート[バイオシミラーの世界市場予測:製品別(インスリン、インターフェロン、エタネルセプト、インフリキシマブ、リツキシマブ、グルカゴン、カルシトニン)、製造別(社内、契約)、疾患別(腫瘍、慢性疾患、血液疾患、自己免疫疾患)、地域別] ( Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025 / BT 2160) 販売に関する免責事項
[バイオシミラーの世界市場予測:製品別(インスリン、インターフェロン、エタネルセプト、インフリキシマブ、リツキシマブ、グルカゴン、カルシトニン)、製造別(社内、契約)、疾患別(腫瘍、慢性疾患、血液疾患、自己免疫疾患)、地域別] ( Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025 / BT 2160) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆